With the proliferation of GLP 1s globally, a new study published in the MJA aims to provide an estimate of the number of adults eligible for TGA approved medicine for chronic weight management.
At least four in ten adults are eligible for the drug and hundreds of thousands are eligible for the treatment of secondary prevention of heart disease.
My name is Sally Block, the MJA’s news and online editor.
“The MJA acknowledges the Traditional Owners and Custodians of the land on which we live and work across Australia. This podcast was recorded on the lands of the Wangal people. I pay my respects to their Elders past and present.”
Co-author and PhD candidate Jasmin Castrillon joins me to talk about the research.
